PharmaTimesOriginal article
Teitur reports positive early data for Parkinson’s peptide TT‑P34
Phase 1positiveTT-P34Positive
AI Analysis
Summary
Teitur reported positive Phase 1 trial data for TT-P34, a peptide therapeutic for Parkinson's disease, demonstrating strong safety profile and CNS exposure.
Clinical Trial Data
Phase
Phase 1
Primary Endpoint
Met
Outcome Details
Strong safety and CNS exposure demonstrated
Importance:5/10
Sentiment:
0.70
Parkinson's diseasepeptide therapeuticPhase 1CNSsafety
Read the original article
Published by PharmaTimes on September 14, 2026 9:27 AM